Abstract: For example, therapeutic methods and the like for novel IL-8-related diseases using an IL-8 signal inhibitor are provided. Alternatively, for example, therapeutic methods and the like for known or novel IL-8-related diseases using a novel anti-IL-8 antibody are provided.

Abstract: It is an object of the present invention to provide a detoxified secretome extract of a culture supernatant having high efficacy and high safety, and a method for producing the same. According to the present invention, provided is a detoxified secretome extract of a culture supernatant of mesenchymal stem cells or progenitor cells derived from the mesenchymal stem cells, wherein the detoxified secretome extract comprises at least one of IGFBP, HGF, VEGF, PDGF, EGF, KGF (FGF-7), PDGFR, TGF?, and TGF? secreted by the mesenchymal stem cells or the progenitor cells derived from the mesenchymal stem cells, and wherein lactic acid and ammonia that are metabolic waste products caused by the mesenchymal stem cells or the progenitor cells derived from the mesenchymal stem cells are removed from the detoxified secretome extract.

Abstract: Provided is a temporary treatment medium for inhibiting embryo developmental arrest due to manipulation of an embryo or the like. A temporary treatment medium according to the present invention reduces damage to an in-vitro culture due to manipulation thereof, said in-vitro culture containing one of pluripotent stem cells, reproductive cells, a fertilized egg, and an embryo or any combination thereof. For this purpose, the temporary treatment medium contains a cytoskeleton regulator and/or an apoptosis inhibitor. The cytoskeleton regulator and/or the apoptosis inhibitor is preferably an Rho kinase inhibitor. Specifically, a Rock inhibitor can be used as the Rho kinase inhibitor. The Rock inhibitor is, for example, Y-27632. The temporary treatment medium is used for treating an in-vitro culture for a specific period before and/or after manipulation involving damage thereto.

Abstract: The present invention provides a recombinant adeno-associated virus (rAAV) vector for treating a blood coagulation-related disease to provide a novel gene therapy means for hemophilia. The virus vector comprises a virus genome comprising a liver-specific promoter sequence and a polynucleotide sequence encoding a genome editing means operably linked to the promoter sequence, wherein the genome editing means is (a) a means comprising CRISPR/Cas9 composed of a Cas9 protein and a guide RNA (gRNA) and a repair gene, or (b) a means comprising CRISPR/Cas9 composed of a Cas9 protein and a gRNA, and the gRNA comprises a nucleotide region complementary to a part of a region related to expression of a disease-related protein on the genome of a patient and a region that interacts with the Cas9 protein.

Abstract: The present invention provides a means for transferring a therapeutic gene of interest into a nervous system cell by a highly-efficient and simpler means. More specifically, the present invention provides a recombinant vector that uses an adeno-associated virus (AAV), a method for manufacturing the recombinant vector, and a method for using the recombinant vector. More specifically, recombinant adeno-associated virus virions, which are capable of passing through the brain-brain barrier, for transferring a therapeutic genes of interest into a nervous system cell in a highly-efficient manner, a drug composition containing the recombinant adeno-associated virus virions, a method for manufacturing the recombinant adeno-associated virus virions, and a kit or the like are provided.

Abstract: A medical instrument, comprising a flexible strap portion having a proximal end and a distal end; a head portion distally extending from and connected to the distal end of the strap portion; and a tail portion proximally extending from and connected to the proximal end of the strap portion; wherein the head portion and the strap portion have a locking feature that allows the strap portion to be tightened to the head portion at a desired position, a loop having a desired size composed of a distal end side part of the strap portion and the head portion can be formed when tightened by the locking feature, and a plurality of features for keeping connected to thread are along the longitudinal direction on at least the distal end side part of the strap portion that forms the loop.

Abstract: A medical instrument, comprising a flexible band body having a distal end and a proximal end; a flexible first rod-shaped body having a distal end and a proximal end; and a flexible second rod-shaped body having a distal end and a proximal end, wherein the distal end of the band body and the proximal end of the first rod-shaped body are connected, the distal end of the first rod-shaped body and the proximal end of the second rod-shaped body are connected via a connecting portion, the band body is more flexible than the first rod-shaped body and the second rod-shaped body, the second rod-shaped body has a locking part, the band body has a locking corresponding part, when tightened the locking part and the locking corresponding part, the proximal end of the first rod-shaped body and the distal end of the second rod-shaped body are connected via a part of the band body, the connecting portion is inflected, and a loop having a desired size can be formed by the first rod-shaped body, the second rod-shaped body and

Abstract: A method for preparing a stromal vascular fraction from an adipose tissue, including a step of treating an adipose tissue with an enzyme solution containing a collagenase and a neutral protease, preferably an enzyme solution free of clostripain and thermolysin, and showing not less than 1 U neutral protease activity with respect to 10,000 U collagenase activity, and recovering cells is provided by the present invention.

Abstract: The purpose of the present invention is to provide a viscoelastic composition having excellent operability, which is suitable for use in securing the field of view of an endoscope when opaque dark-colored liquid accumulates inside a canal and obstructs the field of view of the endoscope, the viscoelastic composition securing the field of view by pushing the liquid aside, and to provide a method for securing the field of view of an endoscope using the viscoelastic composition. The viscoelastic composition for securing the field of view of an endoscope comprises a substance having viscoelastic properties and water, preferably has a hardness of 550 N/m2 or less, a viscosity (25° C.) of 200 to 2,000 mPa·s, and a loss tangent of 0.6 or less, and more preferably has an electrical conductivity of 250 ?S/cm or less. The method for securing the field of view of an endoscope comprises feeding the viscoelastic composition from a proximal part of the endoscope, through a channel, into a distal part of the endoscope.

Abstract: This tool is for treating an excised end of a body organ and is provided with: a long and thin, flexible first band section having a distal end and a proximal end that are made of a biodegradable-absorptive polymer; a long and thin, flexible second band section having a distal end and a proximal end that are made of a biodegradable-absorptive polymer; and a first locking section having a first ratchet claw made of a biodegradable-absorptive polymer, wherein the first locking section is formed at the distal end of the second band section, the distal end of the first band section and the proximal end of the second band section are joined together, at least one ratchet tooth that is capable of meshing with the first ratchet claw is formed on the external surface of the first band section, and the engagement of the ratchet tooth with the first ratchet claw forms a flattened ring which is used to bind a body organ so as to ligate a tube or cavity that opens at an excised end of the body organ.

Abstract: The present application relates to a method for reestablishing stem cells capable of forming chimeras, and cells obtained by the method. The method of the present invention is a technique for monocloning stem cells, for example, capable of forming chimeras from a heterogeneous cell population to obtain high-quality stem cells.

Abstract: Provided is a novel gene therapy means for neurological diseases including epilepsy. The present invention provides: a recombinant adeno-associated virus vector for use in the treatment of neurological diseases including epilepsy, which comprises a polynucleotide encoding a protein capable of improving the excitation-inhibiting function of an inhibitory synapse in vivo, preferably neuroligin-2 protein; a pharmaceutical composition comprising said recombinant vector; and others. The present invention also provides a method for treating a disease such as epilepsy using the recombinant vector.

Abstract: A means for substantially improving mitochondrial dysfunction is provided. An aspect of the present invention relates to an agent for improving mitochondrial dysfunction, having a compound represented by the following formula, a stereoisomer or a salt thereof, or a solvate thereof, as an active ingredient. Another aspect of the present invention relates to a medicament or a pharmaceutical composition having the aforementioned compound, a stereoisomer or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, as an active ingredient, for use in preventing or treating a disease or symptom caused by mitochondrial dysfunction.

Abstract: This tool is for treating an excised end of a body organ and is provided with: a long and thin, flexible first band section having a distal end and a proximal end that are made of a biodegradable-absorptive polymer; a long and thin, flexible second band section having a distal end and a proximal end that are made of a biodegradable-absorptive polymer; and a first locking section having a first ratchet claw made of a biodegradable-absorptive polymer, wherein the first locking section is formed at the distal end of the second band section, the distal end of the first band section and the proximal end of the second band section are joined together, at least one ratchet tooth that is capable of meshing with the first ratchet claw is formed on the external surface of the first band section, and the engagement of the ratchet tooth with the first ratchet claw forms a flattened ring which is used to bind a body organ so as to ligate a tube or cavity that opens at an excised end of the body organ.

Abstract: A blood pressure-related information display device, for visualizing and displaying information relating to blood pressure surges, is provided with: a blood pressure surge detection unit which, from time series data of blood pressure which changes linked to the subject's pulse, detects a blood pressure surge on the basis of a preset determination standard; a bodily state input unit which, together with the time series data of blood pressure, inputs bodily state information which indicates the bodily state of the subject; an extraction unit which extracts a feature value of the blood pressure surge; a statistical processing unit which performs statistical processing of the extracted feature value of the blood pressure surge; a calculation unit which calculates a feature value of the subject's bodily state; a display processing unit which performs processing for displaying, on a display screen, the correlation between the feature value of the blood pressure surge which was subjected to statistical processing, a

Abstract: According to the present invention, blood pressure surges are detected from time-series data on blood pressure of a subject that varies with pulsation based on predetermined determination criteria. For each blood pressure surge thus detected, an envelope connecting a plurality of pulse-corresponding peaks forming the blood pressure surge is acquired as an individual waveform. Statistical processing is performed on a plurality of individual waveforms to obtain a representative waveform and waveform variation among the blood pressure surges in the time-series data. On a display screen, a curve indicating the representative waveform is displayed with the curve superimposed on a region indicating the waveform variation among the blood pressure surges.

Abstract: According to the present invention, blood pressure surges is detected from time-series data on blood pressure of a subject that varies with pulsation based on predetermined determination criteria. A feature amount indicating a characteristic of each blood pressure surge thus detected is obtained. Statistical processing is performed on an occurrence number of the blood pressure surges thus detected and/or the feature amount to obtain a statistical amount for each of time slots. A required attention degree indicating a level of attention being required to the blood pressure surge is obtained for each of the time slots based on the statistical amount of the occurrence number of the blood pressure surges and/or the feature amount. The required attention degree thus obtained and/or the statistical amount are displayed side by side for each of the time slots on a display screen.

Abstract: Provided is a biomarker capable of specifically diagnosing acute kidney injury. An acute kidney injury-specific biomarker is a miRNA that is primarily present in the blood. The miRNA is miRNA-5100. Furthermore, miRNA-5100 can be used as a method for diagnosing acute kidney injury. In this diagnosis, when the expression of miRNA-5100 is decreased in the blood, it is diagnosed as acute kidney injury. As an acute kidney injury test kit, it is also possible to include a reagent for measuring miRNA-5100.

Abstract: Provided are antibacterial phages that selectively kill bacteria having a drug resistance gene or the like. Antibacterial phage for this includes CRISPR-Cas13a with a target sequence that recognizes a specific gene as a target. This target sequence is designed as a spacer sequence for crRNA of 14-28 bases. Specific genes are drug resistance genes and toxins. The drug resistance genes are included in bacterial genomes and/or plasmids having one or any combination of the group including: methicillin-resistant Staphylococcus aureus, vancomycin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, penicillin-resistant pneumococcus, multidrug-resistant Pseudomonas aeruginosa, multidrug-resistant Pseudomonas aeruginosa, carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant cephalosporins, third-generation cephalosporin-resistant Pseudomonas aeruginosa, third-generation cephalosporin-resistant E. coli, and fluoroquinolone-resistant E. coli.

Abstract: For example, therapeutic methods and the like for novel IL-8-related diseases using an IL-8 signal inhibitor are provided. Alternatively, for example, therapeutic methods and the like for known or novel IL-8-related diseases using a novel anti-IL-8 antibody are provided.